Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2. The previous revision label v3.3.1 is removed.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision: v3.3.1 was added and revision: v3.2.0 was removed from the page, representing a minor metadata update. No visible changes to core content, study details, or functionality were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check30 days agoChange DetectedThe government funding lapse notice about updates and NIH operation status was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check44 days agoChange DetectedMinor cosmetic adjustments to page layout and formatting were observed, with no changes to core trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check73 days agoChange DetectedImportant updates include a notice about potential funding-related outages and current operating status, plus a version bump to v3.2.0. If this is a public-facing page, the new operating status information is the key change.SummaryDifference4%

- Check80 days agoChange DetectedUpdate: Revision from v3.0.2 to v3.1.0. This is a versioning change with no other substantive content alterations.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.